LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical...
Inventiva to present the results of LEGEND Phase IIa combination trial
Inventiva announces screening in PIII trial evaluating lanifibranor has resumed
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from...
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical...
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million...
Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASHSino...
As promising late-stage data reinvigorate the enthusiasm for NASH drugs after years of setbacks, one player is changing up its Phase III plans to capitalize on what it sees as a new regulatory approach at the FDA.
Daix (France), Long Island City (New York, United States), Beijing/Hong Kong (China), September 21 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, and Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm, have entered into a licensing and collaboration agreement (the “Agreement”) to develop and commercialize lanifibranor, Inventiva’s proprietary compound, for the treatment of non-alcoholic steatohepatitis (“NASH”) and potentially other metabolic diseases in mainland China, Hong Kong, Macau and Taiwan (“Greater China”).